Scale with Laerdal in the US Healthtech market
28 January 2026 - 1 January 2027
Trade Mission
Innovation Norway and Laerdal have established a market entry programme for Norwegian healthtech companies aiming to scale internationally. The programme combines Laerdal’s deep expertise in hospital-based innovation with access to leading US health institutions such as Mayo Clinic and Tanner Health.
By combining Laerdal’s deep experience in hospital-based innovation with access to leading US institutions such as Mayo Clinic and Tanner Health, the programme creates a clear pathway from innovation to real-world impact.
Meet the companies
Why the US matters
The United States is the world’s largest and most influential market for health technology — and a critical arena for testing scalable solutions.
- Annual healthcare spending of USD 4.3 trillion, representing 18% of GDP
- A sector employing more than 20 million people
- Home to some of the world’s most advanced hospital systems
- Facing shared global challenges such as workforce shortages and demographic change
- 55 million Americans are aged 65+ today, expected to reach 73 million by 2030
With a healthcare system largely driven by private hospitals and insurers, the US offers faster validation and commercialisation compared to many European markets.
A structured journey to market
The programme follows a four-phase structure, designed to reduce risk and build readiness step by step.
Phase 1: Identifying market potential
Based on real needs in the US healthcare sector, 15 Norwegian companies are selected for an initial assessment of their readiness and relevance for the US market.
Phase 2: Validation and gap analysis
Companies take part in 2–4 digital and physical workshops in Norway, meeting representatives from leading US hospital systems. The focus is on regulatory, commercial, product, financial and operational readiness, resulting in a clear gap analysis.
Phase 3: Clinical partnership and scaling
4–6 companies are invited to the US for market visits and real-world validation through pilot projects and co-creation with hospitals such as Mayo Clinic and Tanner Health. This phase also includes funding support and preparation for EHR integration.
Phase 4: Market acceleration
Through Laerdal’s networks and customer access, companies gain momentum in the US market, supported by scaling strategies and long-term partnerships.
Building confidence for international growth
Through Laerdal’s enabling platform and close collaboration with leading US health institutions, the programme offers Norwegian companies:
- Direct access to clinical networks and decision-makers
- First-hand insight into how US hospital systems operate
- Opportunities for clinical validation and co-creation
- A structured pathway to international scaling
Together, Innovation Norway and Laerdal are helping Norwegian healthtech companies turn strong ideas into global solutions, using strategic US partnerships as a springboard for long-term growth.
Contact us
Get in touch with us for more information.
Important conditions
Companies must adhere to standards for responsible business conduct, including Environmental, Social, and Governance (ESG) criteria.
Participants are expected to operate in accordance with the UN Guiding Principles on Business and Human Rights and the OECD Guidelines for Multinational Enterprises on Responsible Business Conduct. This entails conducting business responsibly, respecting human rights, ensuring decent working conditions, safeguarding environmental considerations, and actively preventing corruption.
Companies must carry out their own due diligence assessments (risk assessments) to identify, prevent, and mitigate potential adverse impacts.